International legal practice Osborne Clarke advises a syndicate of investors led by Gilde Healthcare and Versant Ventures with additional support of MRL Ventures Fund in the EUR 16 million financing round of Lava Therapeutics.
The funding will support development of LAVA’s proprietary pipeline of bispecific gamma-delta (γδ) T cell engagers for the treatment of cancer.
Osborne Clarke’s market leading venture capital team is considered a go-to practice. The team across Europe, Asia and the US combine extensive market knowledge and deep sector expertise to support companies throughout all stages of their developments, from start-up to later stage and growth capital funding, strategic M&A and exits, acting for founders, companies, and financial and strategic investors. The team has particular expertise in the tech, media and comms, financial services and life sciences sectors.